Global Regenerative Medicine Partnering Terms and Agreements 2016-2023


The Global Regenerative Medicine Partnering Terms and Agreements 2016-2023 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2023
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Regenerative Medicine Partnering Terms and Agreements 2016-2023 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in regenerative medicine 
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for regenerative medicine and stem cells


The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.


This report provides details of the latest regenerative medicine agreements announced in the life sciences since 2016.


The report takes the reader through a comprehensive review regenerative medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering regenerative medicine partnering deals.


The report presents financial deal term values for regenerative medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the regenerative medicine partnering field; both the leading deal values and most active regenerative medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 1,700 online deal records of actual regenerative medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of regenerative medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading regenerative medicine deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in regenerative medicine dealmaking with a brief summary followed by a comprehensive listing of regenerative medicine deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since Jan 2016. The chapter is organized by specific regenerative medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by regenerative medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine partnering and dealmaking since 2016.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine technologies and products.


Key benefits


Global Regenerative Medicine Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:


  • In-depth understanding of regenerative medicine deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual regenerative medicine contracts entered into by leading biopharma companies
  • Identify most active regenerative medicine dealmakers since 2016
  • Insight into terms included in a regenerative medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Regenerative Medicine Partnering Terms and Agreements 2016-2023 is intended to provide the reader with an in-depth understanding and access to regenerative medicine trends and structure of deals entered into by leading companies worldwide.


Regenerative Medicine Partnering Terms and Agreements includes:


  • Trends in regenerative medicine dealmaking in the biopharma industry since 2016
  • Access to headline, upfront, milestone and royalty data
  • Access to regenerative medicine contract documents
  • Leading regenerative medicine deals by value since 2016
  • Most active regenerative medicine dealmakers since 2016


In Global Regenerative Medicine Partnering Terms and Agreements 2016-2023, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Regenerative Medicine Partnering es and Agreements 2016-2023 report provides comprehensive access to available deals and contract documents for over 1,700 regenerative medicine deals.


Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Regenerative Medicine Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:


  • In-depth understanding of regenerative medicine deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual regenerative medicine contracts entered into by leading biopharma companies
  • Identify most active regenerative medicine dealmakers since 2016
  • Insight into terms included in a regenerative medicine partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in regenerative medicine dealmaking


2.1. Introduction

2.2. Regenerative medicine partnering over the years

2.3. Most active regenerative medicine dealmakers

2.4. Regenerative medicine partnering by deal type

2.5. Regenerative medicine partnering by therapy area

2.6. Deal terms for regenerative medicine partnering

2.6.1 Regenerative medicine partnering headline values

2.6.2 Regenerative medicine deal upfront payments

2.6.3 Regenerative medicine deal milestone payments

2.6.4 Regenerative medicine royalty rates


Chapter 3 – Leading regenerative medicine deals


3.1. Introduction

3.2. Top regenerative medicine deals by value


Chapter 4 – Most active regenerative medicine dealmakers


4.1. Introduction

4.2. Most active regenerative medicine dealmakers

4.3. Most active regenerative medicine partnering company profiles


Chapter 5 – Regenerative medicine contracts dealmaking directory


5.1. Introduction

5.2. Regenerative medicine contracts dealmaking directory


Chapter 6 – Regenerative medicine dealmaking by technology type




Appendix 1 – Regenerative medicine deals by company A-Z

Appendix 2 – Regenerative medicine deals by stage of development

Appendix 3 – Regenerative medicine deals by deal type

Appendix 4 – Regenerative medicine deals by therapy area

Deal type definitions

Further reading


About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Regenerative medicine partnering since 2016

Figure 2: Active regenerative medicine dealmaking activity– 2016 to 2023

Figure 3: Regenerative medicine partnering by deal type since 2016

Figure 4: Regenerative medicine partnering by disease type since 2016

Figure 5: Regenerative medicine deals with a headline value

Figure 6: Regenerative medicine deals with an upfront value

Figure 7: Regenerative medicine deals with a milestone value

Figure 8: Regenerative medicine deals with a royalty rate value

Figure 9: Top regenerative medicine deals by value since 2016

Figure 10: Most active regenerative medicine dealmakers 2016 to 2023

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2seventy bio, 3D-Side, 3D Medicines, 3D Systems, 3SBio, 4basebio Discovery, 4D Molecular Therapeutics, 180 Life Sciences, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, A*STAR’ Institute of Molecular and Cell Biology, A2 Biotherapeutics, AavantiBio, AAVnerGene, Abbvie, Abby Grace Foundation, Abcam, AbCellera Biologics, Abeona Therapeutics, Abingworth Management, Abintus Bio, ABL Bio, Abound Bio, Abu Dhabi Stem Cells Center, Abveris, Abzena, Accelerated Biosciences, Accelerator for Technological Research in Genomic Therapies, Accellix, Accellta, Accenture, AccuResearch, ACEA Biosciences, Acepodia, Aceso Life Science, aCGT Vector, Achilles Therapeutics, Actinium Pharmaceuticals, ACT Therapeutics, ActualEyes, AdAlta, Adaptimmune, Adaptive Biotechnologies, Adicet Bio, Adva Biotechnology, Advanced Biological Innovation and Manufacturing, Advanced BioScience Laboratories, Advanced Biotherapeutics Consulting, Advanced Regenerative Manufacturing Institute, Aethon Therapeutics, Aevitas Therapeutics, Affimed Therapeutics, Affini-T Therapeutics, Affinia Therapeutics, AffyXell Therapeutics, Agathos Biologics, AGC Asahi Glass, AGC Biologics, Ageless Biotech, AgeX Therapeutics, Agilis Biotherapeutics, AgonOx, AiVita Biomedical, Akadeum Life Sciences, Akashi Therapeutics, Akouos, Akoya Biosciences, Alaunos Therapeutics, Alcyone Lifesciences, Alder Biopharmaceuticals, Alder Therapeutics, Aldevron, Aleta Biotherapeutics, Alkem Laboratories, Allele Biotechnology and Pharmaceuticals, Allen Institute for Brain Science, Allergan, Alliance for Cancer Gene Therapy, Alliance for Regenerative Medicine, Allogene Overland Biopharm, Allogene Therapeutics, Alloplex Biotherapeutics, AlloSource, AlloVir, AllStripes, Almirall, Almog Diagnostic, Alnylam Pharmaceuticals, Alpha Biopharma, Alphageneron Pharmaceuticals, Alpha Teknova, Alpine Immune Sciences, ALS Finding a Cure Foundation, Altheia Science, Altor BioScience, ALTuCELL, Amarna Therapeutics, Ambys Medicines, American Association of Neuromuscular & Electrodiagnostic Medicine, American CryoStem, American Gene Technologies, American National Multiple Sclerosis Society, American Society of Gene and Cell Therapy, American Society of Hematology, American Type Culture Collection (ATCC), AmerisourceBergen, Amgen, Amicus Therapeutics, Amryt Pharma, Anagenesis Biotechnologies, Anew Medical, Angionetics, Angiostem, Ankarys Therapeutics, Annapurna Therapeutics, Antengene, Anthony Nolan, Antibe Therapeutics, Antion Biosciences, Apceth, Apeiron Biologics, APEX Biologix, Apic Bio, Apollo Therapeutics, Appia Bio, Applied Cells, Applied DNA Sciences, Applied Genetic Technologies, Applied StemCell, Aquitaine Science Transfert (SATT Aquitaine), SAS Group, Arbele, Arbor Biotechnologies, Arcellx, Arch Therapeutics, Arctic Vision, Arranta Bio, Arsenal Biosciences, Artisan Bio, Artiva Biotherapeutics, Aruvant Sciences, Asahi Kasei, Ascendance Biotechnology, Ascenion, ASC Therapeutics, Asklepios Biopharmaceutical, Aspect Biosystems, Assembly Biosciences, Astellas Institute for Regenerative Medicine, Astellas Pharma, Astellas Pharma US, Astem, Asterias Biotherapeutics, AstraZeneca, Atara Biotherapeutics, Atelerix, Athenex, Athersys, ATMPS, ATP, Atvio Biotech, Audentes Therapeutics, Aurora BioPharma, Australian Research Council, Autolomous, Autolus, Avacta, Avactis Biosciences, Avalon GloboCare, Avance Biosciences, Avectas, Avellino Labs, Avery Therapeutics, AveXis, Avista Therapeutics, Avita Therapeutics, Avrobio, Avvinity Therapeutics, Axcelead Drug Discovery Partners, Axelys, Axiogenesis, Axis Therapeutics, AxoSim, Axovant Gene Therapies, Aziyo Biologics, B-MoGen Biotechnologies, Banner MD Anderson Cancer Center, Barbara Ann Karmanos Cancer Institute, Baxalta, Baxter International, Bayer, Baylor College, Baylor College of Medicine, B Braun, Beam Therapeutics, Be Biopharma, Beckman Research Institute of City of Hope, BeiGene, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Ben-Gurion University, Benaroya Research Institute, Benitec Biopharma, Bennu Pharmaceuticals, Berkshire Sterile Manufacturing, Be The Match BioTherapies, Beyond Type 1, BIA Separations, Bill and Melinda Gates Foundation, Bio-Techne, Bio-Tissue, BioAtla, BioBridge Global, BioCanRx, BioCardia, BioCentriq, Biocomposites, BioCurate, BioCure, BiocurePharm, Biocytogen, BioEclipse Therapeutics, Biofourmis, Biogen, BioInvent, BioLab Sciences, BioLamina, BioLife Plasma Services, BioLife Solutions, BiolineRX, Biological Industries, Biologics Consulting Group, biologistex CCM, BioMagnetic Solutions, BioMarin Pharmaceutical, Biomed, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Bionic Sight, Bionomics, BioNTech, bioRASI, BioRestorative Therapies, Biosceptre International, BioSenic, Biositu Pharmaceutical Technology, Biosolution, BioSpherix, BioStem Life Sciences, BioStem Technologies, BioSurfaces, Biotechnology and Biological Sciences Research Council (BBSRC), BioTherapeutic Labs, Bioventus, Bioverativ, Bird Foundation, Bit Bio, Blackstone, Blood Centers of America, Bluebird Bio, Bluebridge Technologies, Bluepha, Blueprint Genetics, BlueRock Therapeutics, Boehringer Ingelheim, Bone Biologics, BoneSupport, Bone Therapeutics, BoyaLife, Bpifrance, Brain Research Through Advancing Innovative NeurotechnologiesInitiative, BrainStorm Cell Therapeutics, Brammer Bio, BriaCell Therapeutics, BridgeBio Pharma, Brigham and Women's Hospital, Bright Optical, BrightPath Biotherapeutics, Bristol-Myers Squibb, Brooklyn ImmunoTherapeutics, c-LEcta, C3i, Cabaletta Bio, Caladrius Biosciences, Calidi Biotherapeutics, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calimmune, CAMP4 Therapeutics, Canada-Israel Industrial R&D Foundation, Canadian National Transplant Research Program, CANbridge Pharmaceuticals, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Research Technology, Cancer Research UK, Candel Therapeutics, Capricor Therapeutics, Capsida Biotherapeutics, Caravan Biologix, CareDx, CareNet, Caribou Biosciences, Carina Biotech, Carisma Therapeutics, Carolina BioOncology Institute, CARsgen, Cartesian Therapeutics, Cartherics, Casebia Therapeutics, Case Western Reserve University, CASI Pharmaceuticals, Castle Creek Biosciences, Catalent, Catamaran Bio, Catholic University Leuven, CavoGene LifeSciences, CDISC, Cedars-Sinai Health System, Celdara Medical, Celgene, Cell-Easy, Cell2in, Cell and Gene Therapy Catapult, Cell Applications, Cellares, Cellaria Biosciences, Cell Care Therapeutics, Cell Cure Neurosciences, Cell Design Labs, Cellect Biotechnology, Cellectis, Cellectricon, Cellenkos, Cellevolve Bio, CellGenix, Cellinfinity Bio, Celling Biosciences, CELLINK, Cellistic, Cell Medica, Cell Mogrify, Cell One Partners, CellOrigin Biotech, Cell Point, CellPoint, CellProThera, CellReady, CellSpring, Celltex Therapeutics, Cellthera Pharma, Cell Therapy, Cell Therapy Catapult, Cell Therapy Manufacturing Center, Cellular Biomedicine, Cellular Dynamics International, Cellular Engineering Technologies, Cellular Logistics, Cellular Origins, Cellusion, Cellvation, CellVax Therapeutics, Celregen, Celsius Therapeutics, Celularity, Celyad, Censo Biotechnologies, Centauri Therapeutics, Center for Breakthrough Medicines, Center for International Blood and Marrow Transplant Research, Centogene, Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Centurion Therapeutics, Century Therapeutics, Cerhum, Certara, Cesca Therapeutics, Cevec Pharmaceuticals, CgBio, Champions Oncology, Charite Universitatsmedizin Berlin, Charles River Laboratories, Chart Industries, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Hospital of Pittsburgh, Children's Medical Research Institute, Children's National Hospital, Children's Research Institute, Chimeric Therapeutics, Chimeron Bio, China-Singapore Guangzhou Knowledge City, Chinagene Tech, China Medical System, China Southeast University, Chinese University of Hong Kong, Cincinnati Children’s Hospital Medical Center, Cipla, Citius Pharmaceuticals, City of Hope, Cleara Biotech, ClearPoint Neuro, Clearside Biomedical, Cleveland Clinic, Clinigen, CLS Therapeutics, Co.Don, Coalition for the Advancement of Research and Innovation in Trauma, Coave Therapeutics, Cobra Biologics, CODA Biotherapeutics, Code Biotherapeutics, Codexis, Codiak BioSciences, Coeptis Therapeutics, Cognate BioServices, CoImmune, Collagen Solutions LLC, Collplant, Columbia University, Combangio, CombiGene, Conkwest, Convelo Therapeutics, Cook Biotech, Cooperative Research Centre for Cell Therapy Manufacturing, Copenhagen University Hospital, Copernicus Therapeutics, Cord Blood Registry, Corestem, CorMatrix Cardiovascular, Corning, Cosmotec, CPI International, Creative Destruction Lab, Creative Medical Technologies, CRISPR Therapeutics, Crown Bioscience, Cryolife, CryoPort, CSafe Global, CSL Behring, Cue Biopharma, Curasan, Curate Biosciences, CureCell, Cure Duchenne, Cure Genetics, Cure Therapeutics, Cyagen Biosciences, Cynata Therapeutics, Cyprium Therapeutics, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cytiva, CytoImmune Therapeutics, CytoLynx Therapeutics, CytoMed Therapeutics, Cytonet, Cytoo, Cytori Therapeutics, CytoSen Therapeutics, Cytovant Sciences, CYTOVIA Therapeutics, DAAN Bio Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, Dana-Farber Cancer Institute, Danaher, DanausGT Biotechnology, Dartmouth College, Decibel Therapeutics, Deep Science Ventures, Deerfield Management, Defense Advanced Research Projects Agency, DefiniGEN, Defymed, Deloitte, Dendreon, Denovo Biopharma, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, DePuy, DermapenWorld, Deverra Therapeutics, Diabetes Research Institute, Diamond Pharma Services, DigiLab, DiNAQOR, Diomics, Direct Biologics, DNA Script, Dragonfly Therapeutics, Duke-NUS Graduate Medical School Singapore, Duke University, DuPont Pioneer, Dyno Therapeutics, Eclipse Regenesis, Ecole Polytechnique de Montreal, Eden BioCell, EdiGene, Editas Medicine, EditForce, Edith Wolfson Medical Center, eGenesis, Egle Therapeutics, Eiger BioPharmaceuticals, Eikonoklastes Therapeutics, Elanix Biotechnologies, Eledon Pharmaceuticals, Elevai Labs, ElevateBio, Elicio Therapeutics, Eli Lilly, Elixirgen, Elpis Biomed, Embleema, Emercell, Enamine, Endocyte, Endogena Therapeutics, Enlivex, ENPICOM, Ensoma, Enterprise Ireland, Entrada Therapeutics, Enzyvant Science, eQcell, Erasmus University Medical Center, ERS Genomics, Erytech, Escape Therapeutics, Eterna Therapeutics, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Eurostars, Eureka Therapeutics, European Society for Organ Transplantation, European Union, European Wellness Biomedical Group, Eutilogics, EV Biologics, Everads Therapy, Evercyte, Eversana, Evogene, Evotec, Evozyne, Exacis Biotherapeutics, ExcellaBio, ExCellThera, Excision BioTherapeutics, ExonanoRNA, Exopharm, Exothera, Exploit Technologies, Expression Therapeutics, Exuma Biotech, F1 Oncology, Facial Pain Research Foundation, Factor Bioscience, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), Feinstein Institute for Medical Research, Feldan Therapeutics, FerGene, Ferring Pharmaceuticals, Fibrocell Science, FibroGenesis, FineImmune Biotechnology, FIT Biotech, FKD Therapies, FloDesign Sonics, Florica Therapeutics, Fluidigm, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Forcefield Therapeutics, Forge Biologics, Formula Pharmaceuticals, Fortress Biotech, Forty Seven, Fosun Pharmaceutical, Foundation Fighting Blindness, Foundation to Fight H-ABC, Fraunhofer IGB, Fraunhofer Institute for Molecular Ecology (IME), Fred Hutchinson Cancer Research Center, Freeline Therapeutics, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, Fujifilm, FUJIFILM Cellular Dynamics, Fujifilm Diosynth Biotechnologies, Fulcrum Therapeutics, Fundacion Progreso y Salud, FutureGen Biopharm, Gadeta, Gaia, Galaxy Pharma, Galderma, Gamida Cell, Gamma Biosciences, GammaDelta Therapeutics, Gates Biomanufacturing Facility, GC Cell, GC LabCell, GE Healthcare, Gemelli Teaching Hospital, GEMoaB, Gen, GenCure, GeneCraft, GenEdit, Genenta Science, Genentech, GeneQuine Biotherapeutics, Generation Bio, Generation Biotech, Generex Biotechnology, Gene Therapy Research Institution, Genethon, Genetic Information Research Institute, Genetrix, Genevant Sciences, Genezen, Gennao Bio, Genpharm, Genprex, Gensaic, GenScript Biotech, GenScript ProBio, Gensight Biologics, GenStem Therapeutics, GentiBio, Genzyme, George Washington University, GeoVax, German Red Cross, German Red Cross Blood Donor Service, Ghent University, Gicell, GigaMune, Gilead Sciences, Ginkgo BioWorks, Gladstone Institutes, GlaxoSmithKline, Global Stem Cell Technology, GlycoBac, Glycostem Therapeutics, Glycotope Biotechnology, Glytherix, Golden Meditech, Goliver Therapeutics, Government of Canada, Government of Ireland, Gracell Biotechnologies, Graphite Bio, Great Ormond Street Hospital (GOSH), Green Cross LabCell, Greenlight Biosciences, Gritstone Bio, Grunenthal, GT Biopharma, Guangzhou Fanen Biotechnology, Guangzhou Xiangxue Pharmaceutical, Gulf Coast Regional Blood Center, Gunze, Gyroscope Therapeutics, H-CYTE, Hadassah Medical Center, HaemaLogiX, Haihe Laboratory of Cell Ecosystem, Hainan Sihuan Pharmaceutical, Halix, Hamad Bin Khalifa University, HanAll Pharmaceuticals, Hannover Medical School, Hansa Biopharma, Hanuman Pelican, Harbour Biomed, Harvard Stem Cell Institute, Harvard University, HCW Biologics, Healios K.K., Healiva, HealthBanks Biotech, Healthcare Royalty Partners, Heartseed, Heat Biologics, HebeCell, HekaBio, Helix BioPharma, Helmholtz Zentrum Munchen, HemaCare, Hemera Biosciences, Hemogenyx, Hemostemix, HepaTx, HiFiBio, Histogen, Histogenics, Hitachi, Hitachi Chemical, Hitech Health, HitGen, HK inno.N, Hoba Therapeutics, Homology Medicines, Hong Kong Baptist University, Hopstem Biotechnology, Horama, Horizon Discovery, Horizon Europe, Hoth Therapeutics, Houston Methodist Research Institute, HSRx Group, Huadong Medicine, Huapont Pharma, Humacyte, Humanigen, Human Life CORD Japan, Hypertrust, IASO Biotherapeutics, Iaso Pharmaceuticals, iBiologics, IDIS Pharma, iECURE, IGEA Clinical Biophysics, Imagine Pharmaceuticals, Immatics Biotechnologies, Immix Biopharma, ImmuneCyte Life Sciences, Immune Therapeutics, Immunis, ImmunityBio, ImmunoCellular Therapeutics, ImmunoChina Pharmaceuticals, Immunomic Therapeutics, ImmunoScape, ImmunXperts, Immusoft, Immusol, Imperial Innovations, Implant Therapeutics, Imugene, IMV, IN8bio, Inceptor Bio, Incyte, Indapta Therapeutics, Indee Labs, Indiana University, Induce Biologics, Inhibrx, INmune Bio, Innate Pharma, InnoBation, Innovare, Innovate UK, Innovative Cellular Therapeutics, Innovent Biologics, Inserm Transfert, Insitro, Instem, Institute of Cancer Research, Institute of Child Health, Institute of Endocrinology, Metabolism, and Reproduction, Institute of Molecular and Clinical Ophthalmology Basel, Institute Of Molecular Biotechnology, Institute of Neurodegenerative Diseases, Instituto de Biologia Experimental e Tecnológica, Institut Pasteur, Integral Molecular, Integra Therapeutics, Intellia Therapeutics, Interbiome, Interius BioTherapeutics, International Society for Cellular Therapy, Intima Bioscience, Intrexon, iNtRON Biotechnology, Invectys, Invetech, Invitae, InVivo Therapeutics, INVO Bioscience, Ion Channel Innovations, Ionis Pharmaceuticals, Iovance Biotherapeutics, I Peace, IQVIA, Isogenica, IsoPlexis, Israeli National Authority for Technological Innovation, Itochu, iTolerance, iVeena Delivery Systems, Iveric Bio, Ixaka, Jacobio Pharmaceuticals, Jadi Cell, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jasper Therapeutics, JCR Pharmaceuticals, jCyte, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, JOINN Laboratories, Josep Carreras Leukaemia Research Institute, JSR, Juniper Biologics, Juno Therapeutics, Juvenile Diabetes Research Foundation, Juventas Therapeutics, JW Therapeutics, Kadimastem, Kangmei Pharma, KangStem Biotech, Karolinska Institute, KBI BioPharma, Keck School of Medicine of USC, Kentucky Organ Donor Affiliates, Keraderm, Kiadis Pharma, Kidswell Bio, Kinesiometrics, Kinetic River, Kings College London, Kiromic Biopharma, Kite Pharma, Kleo Pharmaceuticals, Kogenix, Kolon Life Science, Korea-Israel Industrial R&D Foundation, Kriya Therapeutics, KSQ Therapeutics, Kumamoto University, Kyocera, Kyoto University, Kytopen, Kyverna Therapeutics, L7 Informatics, LabConnect, Laboratoires Thea, Laboratory Corporation of America, LaCell, Lacerta Therapeutics, Lantheus Holding, Lee Moffitt Cancer Center, Legend Biotech, Leibniz-Institut fur Molekulare Pharmakologie, Leiden University, LEITAT, Lentigen, Leona M and Harry B Helmsley Charitable Trust, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, LEXEO Therapeutics, LG Chem, LG Life Sciences, Life Biosciences, Life Edit Therapeutics, LifeLiver, LifeSouth Community Blood Centers, LIfT BioSciences, Ligandal, Ligand Pharmaceuticals, Likarda, Lilly Institute for Genetic Medicine, Liminal BioSciences, Lineage Cell Therapeutics, LineaRx, Link Health, Lion TCR, Live Like Bella Childhood Cancer Foundation, Locana, Locate Bio, Locate Therapeutics, LogicBio Therapeutics, Longeveron, Lonza, Lorem Vascular, Lubeck Institute of Experimental Dermatology, LUCA Science, Lumicks, Luminary Therapeutics, Lund University, Lung Biotechnology, Lupagen, Lupus Foundation of America (LFA), Luye Pharma Group, Lyell Immunopharma, LyGenesis, Lykan Bioscience, Lysogene, Lytix Biopharma, Maastricht University, MabVax Therapeutics, Macomics, Macquarie University, Magenta Therapeutics, MAGiQ Therapeutics, Magnetic Insight, MainPointe, Malaghan Institute, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, MangoGen Pharma, Marasco Laboratory, Marken, Marker Therapeutics, Mark Foundation for Cancer Research, Maryland Stem Cell Research Fund, Maryland Technology Development Corporation, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, MaSTherCell, Matica Biotechnology, Maverick Therapeutics, Mawson Infrastructure, Max-Delbruck Center for Molecular Medicine, Maxcyte, MaxiVAX, Mayo Clinic, McGill University, McKesson, MD Anderson Cancer Center, MDA Venture Philanthropy, MDimune, Medac, Medeor Therapeutics, Medexus Pharmaceuticals, Medical Incubator Japan, Medical Technology Enterprise Consortium, Medical University of Graz, Medical University of South Carolina, Medicine by Design, Medifocus, Medigen Biotechnology, MediGene, Medigen Vaccine Biologics, MedImmune, Medinet, MED Institute, Medipal Holdings, MediSix Therapeutics, Medpace, MeiraGTx, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Mesoblast, Metagenomi, Metrion Biosciences, Michael J Fox Foundation, Michal Morrison, Microsoft, MIGAL Galilee Research Institute, Mill Creek Life Sciences, MilliporeSigma, Miltenyi Biotec, MiMedx, Minaris Regenerative Medicine, Minerva Biotechnologies, Minomic, Minovia Therapeutics, Miromatrix Medical, Mirum Pharmaceuticals, Misonix, Mission Bio, Mitacs, Mitsubishi Tanabe Pharma, Moderna, Molecular Templates, MolMed, Monarch Biosciences, Monomer Bio, MorphoSys, Mount Sinai Medical Center, mSKIL, MSM-Medimpex, MT-Biological Science and Technology, MTF Biologics, Multiclonal Therapeutics, Multimmune, Multiple Myeloma Research Foundation, Mundipharma, Murdoch Childrens Research Institute, Muscular Dystrophy Association, Musculoskeletal Clinical Regulatory Advisers, Mustang Bio, Myeloid Therapeutics, myNEO, Myonexus Therapeutics, Myosana Therapeutics, Myrtelle, myTomorrows, Nagoya University Graduate School of Medicine, Namocell, Nanion, Nanjing KAEDI Biotech, NanoCellect Biomedica, Nano Dimension, Nanoscope Therapeutics, NanoString Technologies, Nanotronics Health, Nanovis, NantKwest, NantOmics, Nanyang Technological University, NASA, Natera, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute for Bioprocessing Research and Training, National Institute for Innovation in Manufacturing Biopharmaceuticals, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, National Organization for Rare Disorders, National Research Council Canada, National Research Council of Canada, National Resilience, National Science Foundation, National Stem Cell Foundation, National Taiwan University Hospital, National University of Ireland, Galway (NUI Galway), National University of Singapore, Nationwide Children’s Hospital, Natural Sciences and  Engineering Research Council of Canada, Ncardia, NEC, NecstGen, Neo Gene Pharm, Neogene Therapeutics, Neon Therapeutics, Netherlands Cancer Institute, NeuExcell, Neukio Biotherapeutics, Neuracle Genetics, Neurgain Technologies, Neurocrine Biosciences, Neurogene, Neurona Therapeutics, Neurophth Therapeutics, New Jersey Innovation Institute, New York Blood Center, New York Medical College, New York Presbyterian/Columbia, Nexcella, Nexel, Neximmune, Next&Bio, Nightstar Therapeutics, Nikon CeLL Innovation, Nippon Shinyaku, Nkarta Therapeutics, NKGen Biotech, NKMax America, Noga Therapeutics, Nohla Therapeutics, Noile-Immune Biotech, Nordic Nanovector, North Carolina State University, Northern Biomedical Research, Northwell Health, Northwestern University, NorthX Biologics, Norwegian Research Council, Notch Therapeutics, NovalGen, Novartis, Novartis Institutes for BioMedical Research, Novasep, NoveCite, Novellus Biopharma, Novellus Therapeutics, Novo Nordisk, Nucleus Biologics, Nuo Therapeutics, NYU Langone Medical Center, Obatala Sciences, Obio, Obsidian Therapeutics, Ocugen, Oculogenex, Ocumension Therapeutics, Odylia Therapeutics, Ohio State University, Olaregen Therapeutix, Omeros, OmniaBio, OncoImmune, Oncolys BioPharma, OncoOne, Oncora Medical, OncoSec Medical, Oncternal Therapeutics, ONI, oNKo-innate, ONK Therapeutics, Ono Pharmaceutical, Ontario Institute for Regenerative Medicine, Onward Therapeutics, Ophthotech, Opsis Therapeutics, Optieum Biotechnologies, Optimeos Life Sciences, Opus Genetics, Orbit Biomedical, Orca Bio, Orchard Therapeutics, Oregon Health Sciences University, Oregon National Primate Research Center, ORFLO Technologies, Organogenesis, Organovo, Organ Technologies, Orgenesis, Ori Biotech, ORIG3N, Orsini Healthcare Specialty Pharmacy, Orthocell, Orthofix Medical, Orthohealing Center Management, Ortho Regenerative Technologies, OSE Immunotherapeutics, Ospedale San Raffaele, Ossium Health, Osteopore International, Outpace Bio, Overland Pharmaceuticals, Ovid Therapeutics, Ovoclinic, Oxford BioMedica, Oxford Biomedica Solutions, Oxford Genetics, Oxford MEstar, Oxgene, OZ Biosciences, P3 Health, PACT Pharma, Palantir, Pall Corporation, Pan American Cancer Treatment Centers, panCELLa, Pancryos, Panion, Pantherna Therapeutics, Papyrus Therapeutics, Paragon Bioservices, Parent Project Muscular Dystrophy, Parkinsons Disease Foundation, Passage Bio, Pathways to Stem Cell Science, Paul Ehrlich Institute, PCT, PDC*line Pharma, PDS Biotechnology, Penn Medicine, Perelman School of Medicine, PersonGen BioTherapeutics, Peter MacCallum Cancer Institute, Pfizer, Phanes Therapeutics, PharmaCell, PharmaCyte Biotech, PharmaEssentia, Pharming Group, Pharmsynthez, Phibro Animal Health, Phio Pharmaceuticals, PhoreMost, Pierre Fabre, PlantArcBio, PlasmidFactory, Plasticell, Plastomics, Platelet BioGenesis, Pluristem Therapeutics, Pluristyx, Plus Therapeutics, Poietis, PolarityTE, Pompeu Fabra University, Population Diagnostics, Portage Biotech, Porton Biologics, Poseida Therapeutics, PreCerv, Precision BioSciences, Predictive Oncology, Pregene Biopharma, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, ProBioGen, Procella Therapeutics, Procyon Technologies, ProMab Biotechnologies, Promethera Biosciences, Prometheus Laboratories, Propagenix, Prostate Cancer Foundation (PCF), ProteinTech, Proteona, ProteoNic, Proteostasis Therapeutics, Provecs Medical, Providence Cancer Institute, PsiOxus Therapeutics, PTC Therapeutics, Pulthera, Puregraft, Pure MHC, Purespring Therapeutics, Q-Gen Cell Therapeutics, Qihan Biotech, Qilu Pharmaceutical, Q Therapeutics, Quebec Consortium for Drug Discovery, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, R4D Biotech, Ray Therapeutics, RCSI University of Medicine and Health Sciences, ReCode Therapeutics, Red One Medical, Refuge Biotechnologies, Regen BioPharma, Regenerative Medicine of China, Regeneron Pharmaceuticals, Regeneus, Regenexx, ReGen Scientific, Regentys, Regenxbio, Rejuvenate Bio, ReLive Biotechnologies, Remedium Bio, ReNeuron, Renovacare, Renova Therapeutics, Renovo, Repertoire Immune Medicines, Replay, Replicel Life Sciences, ReproCell, Rescue Hearing, Research Development Foundation, Research Institute of the Hospital Universitari Vall d'Hebron, Research Products Development Company, Resilience, Resolution Therapeutics, RetroSense Therapeutics, RevBio, Rexgenero, Reyon Pharmaceuticals, Ricoh, Rigenerand, RIKEN Center for Integrative Medical Sciences, RIKEN Yokohama Institute Omics Science Center, Rivaara Immune, Roche, Rocket Pharmaceuticals, Rockland Immunochemicals, Roivant Sciences, RoosterBio, RoslinCT, Roswell Park Cancer Institute, Royal Children’s Hospital, RTI Surgical, Rubedo Life Sciences, Rubius Therapeutics, Rune Labs, Rutgers University, RxBio, RxCell, RXi Pharmaceuticals, Ryne Biotechnology, SalioGen Therapeutics, Salk Institute, Sana Biotechnology, SanBio, Sangamo Therapeutics, Sanofi, San Raffaele Scientific Institute, Santen Pharmaceutical, Santhera Pharmaceuticals, Sapreme Technologies, Sarah Cannon Research Institute, Sarepta Therapeutics, Sartorius, SATT Conectus Alsace, SAVSU Technologies, Scaled Biolabs, ScaleReady, Scenic Biotech, Schepens Eye Research Institute, Scion Solutions, SCM Pharma, Scopus BioPharma, Scottish Enterprise, Scribe Therapeutics, Scripps Research Institute, Scriptr Global, Seattle Children's Hospital, Seattle Children's Therapeutics, Seattle Childrens Research Institute, Secant Medical, Seelos Therapeutics, Selecta Biosciences, Selexis, Semma Therapeutics, Sensorion, Senti Biosciences, Seoul National University, Seraxis, Seres Therapeutics, Sernova, Serotiny, Sexton Biotechnologies, Shanghai Cell Therapy Group, Sharp Edge Labs, Shenzhen Yuanxing Bio-Pharm Science & Technology, Shibuya Kogyo, Shinshu University, Shire Pharmaceuticals, Shoreline Biosciences, Showa Denko, Sigilon Therapeutics, SimonMed Imaging, Singapore Eye Research Institute (SERI), Sinorda Biomedicine, Sinovant Sciences, Sio Gene Therapies, Sirenas, Sirion Biotech, Sirtex Medical, SiSaf, Skyline Therapeutics, Slingshot Biosciences, Smart Immune, SmartPharm Therapeutics, Smartwise, Sofregen Medical, Solentim, Solid Biosciences, Sonnet BioTherapeutics, Sonoma BioTherapeutics, SonoThera, Sorrento Therapeutics, Sosei, Spanish State Research Agency, SparingVision, Spark Therapeutics, Sphere Fluidics, Spinogenix, Spooner Girls Foundation, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Stem Cell Network, Stemcell Technologies, Stemedica Cell Technologies, StemExpress, StemoniX, Stempeutics, StimLabs, St Jude Medical, StrideBio, Strm.Bio, Suneva Medical, Sunovion Pharmaceuticals, SunTerra Biotechnology, Super-T Cell Cancer, Surgalign, Surgical Specialties, Surrozen, Suzhou Porton Advanced Solutions, SwanBio Therapeutics, Syena, Symbasis, Symbiotix Biotherapies, Symvivo, SynGen, Synlogic, Synova Healthcare, Synpromics, Synthego, T-Cure Bioscience, T-TOP Clinical Research, Tactiva Therapeutics, TaiRx, TaiwanBio Therapeutics, Takara Bio, Takeda Pharmaceutical, Takeda Ventures, Talaris Therapeutics, Talee Bio, Tamid Bio, Tantu Therapeutics, Target ALS Foundation, Targovax, Tasly Pharmaceuticals, Taysha Gene Therapies, TC BioPharm, TCR2 Therapeutics, TeamedOn International, Team Sanfilippo, Technology University Dresden, Teijin, Tel Aviv Sourasky Medical Center, Temple University, TeneoBio, Terumo Blood and Cell Technologies, Tessa Therapeutics, Teva Pharmaceutical Industries, Tevard Biosciences, Tevogen Bio, Texas A&M Health Science Center, TFS International, TGen Drug Development, The Cyprus Institute of Neurology and Genetics, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Therabest, Theracell, Theradaptive, Theragene Pharmaceuticals, Theragent, Therakine, Therapeutic Solutions International, Theravectys, The Regents of the University of California, Thermo Fisher Scientific, ThermoGenesis, ThinkCyte, Thomas Jefferson University, Thorne Research, Thought Leadership & Innovation Foundation, Thrive Bioscience, Tianjin CanSino Biotechnology, TiGenix, TissueGene, Tissue Genesis, Tiziana Life Sciences, T Med, Tmunity Therapeutics, TNK Therapeutics, Tocagen, TONIX Pharmaceuticals, Toregem BioPharma, Torque Therapeutics, Toshiba, Touchlight, Trakcel, Transgene, Treadwell Therapeutics, TreeFrog Therapeutics, Trestle Biotherapeutics, TriArm Therapeutics, Trillium Therapeutics, Trinity College Dublin, Triumvira Immunologics, Truveta, TScan Therapeutics, Tu Dresden, Tufts University, Turnstone Biologics, Twist Bioscience, TxCell, Tyris Therapeutics, U CAN-CER VIVE Foundation, UCB, UCL Business, UGA Biopharma, UK Cystic Fibrosis Gene Therapy Consortium, Ulster University, Ultragenyx Pharmaceuticals, Umoja Biopharma, UniQuest, UniQure, United Cargo, United Therapeutics, Universal Cells, Universite Laval, University Ann & Robert H. Lurie Children’s Hospital, University College Dublin, University College London, University Health Network, University Medical Center Groningen, University Medical Center Utrecht, University of Adelaide, University of Alabama, University of Barcelona, University of Basel, University of Birmingham, University of British Columbia, University of California, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of California Santa Barbara, University of Colorado, University of Eastern Finland, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Heidelberg, University of Helsinki, University of Iowa, University of Lausanne, University of Leeds, University of Louisville, University of Manchester, University of Maryland, University of Massachusetts, University of Massachusetts Medical School, University of Minnesota, University of Missouri, University of Montreal, University of North Carolina, University of North Texas Health Science Center, University of Nottingham, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, University of Quebec, University of Queensland, University of Sheffield, University of South Australia, University of Southern California, University of Technology Sydney, University of Tennessee, University of Texas, University of Texas Southwestern Medical Center, University of Tokyo, University of Toronto, University of Victoria-Genome British Columbia Proteomics Centre, University of Virginia, University of Washington, University of Wisconsin-Madison, University Pierre Marie Curie, Upside Biotechnologies, Urovant Sciences, US Army, US Army Institute of Surgical Research (USAISR), US Army Medical Research and Material Command, Utrecht University, UT Southwestern Medical Center, Valitacell, Vanderbilt University, Vascugen, Vaximm, VBL Therapeutics, Vector BioPharma, VectorY Therapeutics, Vedanta Biosciences, Velabs Therapeutics, Veltmeyer MD, Vericel, Verismo Therapeutics, Vertex Pharmaceuticals, Vesigen Therapeutics, Veterans Medical Distributors, ViaCyte, VIB, Victoria University, Vigene Biosciences, ViGeneron, Vineti, Viracta Therapeutics, ViraCyte, Viralgen, Vir Biotechnology, Virginia Commonwealth University, Virica Biotech, Virion Therapeutics, Viroclinics Biosciences, Visikol, Vision Care Group, VistaGen Therapeutics, Vital KSK, Vitruvian Networks, VIVEbiotech, Vivet Therapeutics, Vivo Biosciences, Vizient, VolitionRX, Vor Biopharma, Voyager Therapeutics, VWR International, Vycellix, VyGen-Bio, Vyriad, Wageningen University, Wake Forest Institute for Regenerative Medicine, Wake Forest University, Walking Fish Therapeutics, Walloon Region Investment Fund, Washington University in St Louis, WCTE, Weill Cornell Medical College, Weizmann Institute, Werum IT Solutions, Whitehead Institute, WhiteLab Genomics, Wilson Wolf, WindMIL Therapeutics, WIRB-Copernicus Group, Wisconsin Alumni Research Foundation, Wiseman Cancer Research Foundation, Wistar Institute, W L Gore, Worcester Polytechnic Institute (WPI), WUGEN, WuXi Advanced Therapies, Wuxi Apptec Laboratory Services, WuXi Biologics, Xbiome, Xcell Biosciences, Xencor, Xenetic Biosciences, Xlife Sciences, XNK Therapeutics, Xyphos Biosciences, Y-Biologics, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yinjia Biosciences, Yissum Research Development, YOFOTO (China) Health Industry, Yposkesi, Yufan Biotechnologies, YUMAB, Yumanity Therapeutics, Zelluna Immunotherapy, Zhaotai Group, Zhittya Genesis Medicine, Zimmer Biomet, Ziopharm Oncology, Zogenix

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.